awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33704050-43212221-B443-4A92-A7BD-0D3CDA6929AA
Q33704050-43212221-B443-4A92-A7BD-0D3CDA6929AA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33704050-43212221-B443-4A92-A7BD-0D3CDA6929AA
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
P2860
Q33704050-43212221-B443-4A92-A7BD-0D3CDA6929AA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33704050-43212221-B443-4A92-A7BD-0D3CDA6929AA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
96d2bb466ccccc6f30ac5514c41654c5917c00f9
P2860
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An